According to the study,mutant KRAS ctDNA may be a more accurate and focused biomarker fordetermining how chemotherapy would affect a patient’s advancedPC and for tracking their treatment.28−30 Kruger et al. identifiedKRAS mutations in PC3 using dPCR technology.27 They employed ctDNA KRAS detection and quantification by dPCR asa stand-in marker of tumor load in PC to forecast response and tracktreatment. The gene discussed is KRAS; the disease is neoplasm.